Biocryst Pharmaceuticals buy JPMorgan Chase & Co.
Start price
20.11.23
/
50%
€4.86
Target price
20.11.24
€9.15
Performance (%)
44.15%
End price
21.11.24
€7.00
Summary
This prediction ended on 21.11.24 with a price of €7.00. The BUY prediction by JPMorgan_Chase___Co_ for Biocryst Pharmaceuticals saw massive gains of 44.15%. JPMorgan_Chase___Co_ has a follow-up prediction for Biocryst Pharmaceuticals where he still thinks Biocryst Pharmaceuticals is a Buy. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Biocryst Pharmaceuticals | -3.683% | -3.683% | -11.816% |
| iShares Core DAX® | -0.793% | 4.201% | 19.951% |
| iShares Nasdaq 100 | -2.376% | 0.857% | 4.704% |
| iShares Nikkei 225® | -2.701% | -0.147% | 12.609% |
| iShares S&P 500 | -1.689% | 1.244% | 3.144% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
In the thread Trading Biocryst Pharmaceuticals
Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten
Current prediction by JPMorgan_Chase___Co_ for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€9.37
06.05.25
06.05.25
€11.51
06.05.26
06.05.26
-33.55%
18.12.25
18.12.25
